TCF-001 TRACK (Target Rare Cancer Knowledge) Study
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 400
- 试验地点
- 2
- 主要终点
- Percent of participants who receive a molecularly targeted matched treatment after recommendation from the VMTB.
研究概览
简要总结
This open label, non-randomized, multi-center, pragmatic study aims to establish whether patients with rare tumors can benefit from matched molecular therapy as dictated by their next-generation sequencing (NGS) results.
详细描述
This open label, non-randomized, multi-center, pragmatic study aims to establish whether patients with rare tumors can benefit from matched molecular therapy as dictated by their next-generation sequencing (NGS) results. The study leverages a remote consent and participation approach to open enrollment to all patients with rare tumors within the United States. Traditional, site-based patient consenting and participation is also available for enrollment to the study.
Each participant will undergo comprehensive genomic profiling (CGP) by Foundation Medicine Inc. (FMI) of their tumor as well as plasma circulating cell-free DNA. Plasma circulating cell-free DNA may be additionally collected for repeat CGP at various timepoints during the study.
The CGP findings will be provided by FMI directly to the treating physician and study sponsor TargetCancer Foundation (TCF), with TCF presenting cases with genomic findings to the Virtual Molecular Tumor Board (VMTB). The VMTB will analyze the findings and provide a written report to the treating physician on recommended treatments and/or relevant clinical trials; the treating physician makes all treatment decisions. The resultant treatments and treatment responses will be tracked longitudinally during the term of this study, thus linking molecularly informed treatments to specific patient outcomes.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Factorial
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Provision of signed and dated informed consent form.
- •Stated willingness to comply with all study related blood draws and assessments for the duration of the study.
- •Individuals who are 18 years old or older at the time of consent.
- •Patients with a rare (fewer than 6 cases per 100,000 per year) solid tumor or lymphoma with evaluable disease at baseline. The complete list of included cancers are included in the study protocol; diseases not listed in the study protocol may be enrolled with the approval of the Principal Investigator.
- •May or may not have had qualifying (by Foundation Medicine) comprehensive genomic profiling before the present study. For those who have had qualifying comprehensive genomic profiling performed prior to the present study, the archival specimen tested must have been harvested within 18 months of the baseline visit (i.e. date of consent) of the present study.
- •Willingness to provide existing archived and/or newly collected tissue resulting from standard of care procedures and blood samples for genomic profiling. If the submitted sample is determined to be insufficient for testing, the patient will be considered to be a screen failure.
- •For archival tissue to be used for comprehensive genomic profiling for the present study, that specimen must have been harvested within 18 months of the baseline visit (i.e. date of consent) of the present study.
- •Willingness to provide clinical and medical information to the study team as required.
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0-
- •Ability to read, write and communicate in English.
- •Ability to review and sign a web-based informed consent form, or review and sign an informed consent form in treating physician office.
- •Resides within the United States.
排除标准
- •Participants who are unable to provide informed consent.
- •Participants who are 17 years of age or younger.
- •Participants who are unable to comply with the study procedures.
- •Known existence of an uncontrolled intercurrent illness including, but not limited to, psychiatric illness or social situations that would impair compliance with study requirements.
- •Concurrent active malignancy requiring treatment within 1 year of enrollment, at the discretion of treating physician.
- •Pregnancy or breastfeeding.
- •Any unlisted criteria at the discretion of the treating physician.
研究组 & 干预措施
Cholangiocarcinoma
Eligible patients that present with Cholangiocarcinoma.
干预措施: FoundationOne CDx and FoundationOne Liquid CDx (Diagnostic Test)
Cancer of Unknown Primary (CUP)
Eligible patients with cancer of unknown primary site (CUP).
干预措施: FoundationOne CDx and FoundationOne Liquid CDx (Diagnostic Test)
Other remaining rare cancers (solid tumors & lymphomas)
Eligible patients that meet the definition of rare cancers (incidence of less than 6 per 100,000 in the United States).
干预措施: FoundationOne CDx and FoundationOne Liquid CDx (Diagnostic Test)
结局指标
主要结局
Percent of participants who receive a molecularly targeted matched treatment after recommendation from the VMTB.
时间窗: 2 years
The primary feasibility endpoint is the percent of participants who receive a molecularly targeted matched treatment after recommendation from the VMTB. Point estimates and confidence interval estimations will be calculated for percent of participants on matched treatments.
Progression-free survival (PFS) among participants who received the molecularly targeted matched treatment.
时间窗: 2 years
The primary efficacy endpoint is the progression-free survival (PFS) among participants who received the molecularly targeted matched treatment. Kaplan-Meier estimates will be constructed for time-to-event endpoints, including progression-free survival (PFS). Cox regression analysis will be applied to model PFS by putative covariates such as performance status, type of tumor, prior lines of treatment, and whether matched treatments are received.
次要结局
- Comparison of Tumor Biomarker Profiling to Treatment Outcome.(2 years)